272
Participants
Start Date
November 16, 2021
Primary Completion Date
September 4, 2024
Study Completion Date
September 4, 2024
Ociperlimab
900 mg intravenously (IV) once every 3 weeks (Q3W)
Tislelizumab
200 mg IV Q3W
Carboplatin
Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle
Paclitaxel
75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle
Nab paclitaxel
100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle
Cisplatin
75 mg/m², administered intravenously on Day 1 of each 21-day cycle
Pemetrexed
500 mg/m² administered intravenously on Day 1 of each 21-day cycle
Placebo
Administered intravenously Q3W to match ociperlimab
Klinik Penzing Wien, Abteilung Fur Atemwegs, Vienna
Northern Beaches Hospital, Frenchs Forest
Port Macquarie Base Hospital, Port Macquarie
Border Medical Oncology, East Albury
Olivia Newton John Cancer Wellness and Research Centre, Heidelberg
Peninsula and South Eastern Haematology and Oncology Group, Frankston
Toowoomba Hospital, Toowoomba
Townsville University Hospital, Douglas
Launceston General Hospital, Launceston
Cha Bundang Medical Center, Cha University, BundangGu SeongnamSi
Centre Hospitalier Regional Universitaire de Caen, Caen
Centro Oncologico de Galicia, A Coruña
Ajou University Hospital, Suwon
Complejo Asistencial Universitario de Leon, León
Hospital Universitario Central de Asturias, Oviedo
Ulsan University Hospital, Donggu
Fundacion Instituto Valenciano de Oncologia Ivo, Valencia
Dong A University Hospital, Seogu
Ch Provincial de Castellon, Castellon
St Lukes Hospital, Thessaloniki
Institut Curie, Paris
Hopital Europeen Georges Pompidou, Paris
Hopital Charles Nicolle Clinique Pneumologique, Rouen
Beijing Cancer Hospital, Beijing
Ansteel Group General Hospital, Anshan
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Huashan Hospital Affiliated to Fudan University, Shanghai
Shanghai Pulmonary Hospital, Shanghai
Changzhou Cancer Hospital, Changzhou
Shandong Cancer Hospital, Jinan
Liaocheng Peoples Hospital, Liaocheng
Zhejiang Provincial Peoples Hospital, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Huzhou Central Hospital, Huzhou
The First Hospital of Jiaxing, Jiaxing
Jinhua Municipal Central Hospital, Jinhua
Fujian Cancer Hospital, Fuzhou
Xinqiao Hospital Affiliated to the Army Medical University, Chongqing
Daping Hospital, Third Military Medical University, Chongqing
The First Peoples Hospital of Chenzhou, Chenzhou
Jingzhou Central Hospital, Jingzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Cancer Center of Guangzhou Medical University, Guangzhou
West China Hospital, Sichuan University, Chengdu
The First Hospital of Lanzhou University, Lanzhou
The First Peoples Hospital of Kashgar, Kashgar
Valkyrie Clinical Trials, Los Angeles
University of Iowa Hospitals and Clinics, Iowa City
Comprehensive Cancer Center of Nevada, Las Vegas
Rj Zuckerberg Cancer Center, New Hyde Park
North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists (New York), New York
North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists, Port Jefferson Station
Ny Cancer and Blood Specialists, The Bronx
Xcancerdayton Physician Network, Dayton
Tennessee Cancer Specialist, Knoxville
Texas Oncology Tyler Longview, Austin
Cancer Care Northwest, Spokane Valley
Samsung Medical Center, GangnamGu
Korea University Guro Hospital, GuroGu
Kangbuk Samsung Hospital, JongnoGu
Severance Hospital Yonsei University Health System, SeodaemunGu
Seoul National University Hospital, Seoul
Gangnam Severance Hospital, Yonsei University Health System, Seoul
Lead Sponsor
BeiGene
INDUSTRY